Loading…
Eiko Lifesciences (BSE 540204)₹49.86−1.64%Specialty Chemicals
In the Jun 2026 quarter (consolidated), Eiko Lifesciences reported sales of ₹16.74 Cr, up 56.4% from Jun 2025, and net profit of ₹1.50 Cr, up 36.4% year on year. For the year to Mar 2026, sales were ₹52.58 Cr and net profit ₹5.30 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.76 | 8.15 | 7.48 | 11.28 | 10.70 | 11.66 | 11.97 | 18.35 | 16.74 |
| Expenses | 10.37 | 7.75 | 6.88 | 9.98 | 9.22 | 9.93 | 10.13 | 16.12 | 14.87 |
| Operating Profit | 0.39 | 0.42 | 0.62 | 1.31 | 1.52 | 1.78 | 1.89 | 2.25 | 1.94 |
| OPM % | 3.7% | 5.3% | 8.4% | 11.7% | 14.1% | 15.2% | 15.7% | 12.3% | 11.5% |
| Other Income | 0.25 | 0.12 | 0.11 | 0.63 | 0.26 | 0.29 | 0.34 | 0.12 | 0.44 |
| Interest | 0.02 | 0.03 | 0.02 | 0.06 | 0.04 | 0.09 | 0.06 | 0.11 | 0.12 |
| Depreciation | 0.18 | 0.17 | 0.17 | 0.26 | 0.26 | 0.27 | 0.27 | 0.26 | 0.26 |
| Profit before tax | 0.45 | 0.35 | 0.55 | 1.63 | 1.47 | 1.70 | 1.89 | 2.01 | 1.99 |
| Tax % | 26.1% | 27.8% | 25.0% | 23.8% | 25.0% | 24.6% | 24.7% | 25.8% | 24.5% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.36 | 0.27 | 0.41 | 1.24 | 1.10 | 1.28 | 1.42 | 1.49 | 1.50 |
| EPS (Rs) | 0.31 | 0.23 | 0.34 | 0.85 | 0.67 | 0.80 | 0.89 | 0.92 | 0.92 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 2.37 | 4.28 | 10.39 | 37.67 | 52.58 | 58.72 |
| Expenses | 1.99 | 4.97 | 14.95 | 34.98 | 45.36 | 51.05 |
| Operating Profit | 0.39 | −0.69 | −4.50 | 2.76 | 7.32 | 7.86 |
| OPM % | 16.1% | −15.9% | −43.3% | 7.4% | 13.9% | 13.4% |
| Other Income | 0.03 | 0.03 | 0.00 | 1.19 | 1.15 | 1.19 |
| Interest | 0.08 | 0.18 | 0.23 | 0.16 | 0.35 | 0.38 |
| Depreciation | 0.09 | 0.18 | 0.20 | 0.75 | 1.03 | 1.06 |
| Profit before tax | 0.24 | −0.99 | −4.92 | 3.05 | 7.09 | 7.59 |
| Tax % | 20.0% | −21.0% | −26.8% | 24.5% | 25.2% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.19 | −0.77 | −3.61 | 2.31 | 5.30 | 5.69 |
| EPS (Rs) | 0.32 | −0.70 | −2.99 | 1.87 | 3.72 | 3.53 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 3.83 | 3.83 | 3.83 | 13.77 | 14.37 |
| Reserves | 1.75 | 1.11 | −0.88 | 43.02 | 54.49 |
| Borrowings | 1.73 | 1.36 | 1.60 | 2.75 | 4.72 |
| Other Liabilities | 3.64 | 2.99 | 7.50 | 6.53 | 15.79 |
| Total Liabilities | 10.95 | 9.29 | 12.05 | 66.07 | 89.37 |
| Fixed Assets | 1.67 | 1.70 | 1.74 | 23.03 | 22.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.16 | 1.71 | 0.09 | 7.14 | 15.27 |
| Other Assets | 6.12 | 5.88 | 10.22 | 35.90 | 52.09 |
| Inventories | 3.11 | 2.32 | 3.22 | 5.79 | 3.98 |
| Trade receivables | 1.47 | 0.87 | 1.19 | 10.83 | 20.27 |
| Cash & equivalents | 0.81 | 0.12 | 0.01 | 11.77 | 13.60 |
| Total Assets | 10.95 | 9.29 | 12.05 | 66.07 | 89.37 |
| Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 0.15 | −0.32 | — | 2.77 | 2.24 |
| Cash from investing activity | −0.31 | −0.72 | — | −11.34 | −8.67 |
| Cash from financing activity | −0.54 | 0.94 | — | 6.93 | 8.18 |
| Net cash flow | −0.70 | −0.10 | — | −1.58 | 1.84 |
| Capex | 0.21 | 0.24 | 0.63 | 10.30 | 0.00 |
| Free cash flow | −0.03 | −0.55 | — | −7.49 | 2.24 |
| CFO / OP % | −25.9% | 7.0% | — | 112.0% | 50.1% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 226 | 74 | 41 | 105 | 140 |
| Inventory days | 820 | 288 | 154 | 64 | 35 |
| Days payable | 606 | 174 | 185 | 37 | 111 |
| Cash conversion cycle | 441 | 188 | 12 | 133 | 65 |
| Working capital days | 79 | −3 | −153 | 143 | 127 |
| ROCE % | — | −11.9% | −105.5% | — | 11.1% |
For the Jun 2026 quarter, Eiko Lifesciences reported sales of ₹16.74 Cr, up 56.4% year on year and net profit of ₹1.50 Cr, up 36.4% year on year. The operating margin was 11.5%.
Eiko Lifesciences' sales for the year to Mar 2026 were ₹52.58 Cr; over the last twelve months they were ₹58.72 Cr.
Net profit for the year to Mar 2026 was ₹5.30 Cr, and ₹5.69 Cr over the last twelve months. Earnings per share over the same trailing period were ₹3.53.
Eiko Lifesciences reported borrowings of ₹4.72 Cr at Mar 2026, against cash and equivalents of ₹13.60 Cr.
Cash from operations was ₹2.24 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2.24 Cr.